<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01558427</url>
  </required_header>
  <id_info>
    <org_study_id>2012/156</org_study_id>
    <nct_id>NCT01558427</nct_id>
  </id_info>
  <brief_title>Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer</brief_title>
  <official_title>Salvage Treatment or Active Clinical Surveillance for Oligometastatic Prostate Cancer: a Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer patients diagnosed with a biochemical recurrence and limited metastases are
      conventionally treated with androgen deprivation therapy. However, in patients with limited
      metastatic load, the time to progression might be. Subsequently, active surveillance of these
      patients until progression might defer the start of androgen deprivation therapy (ADT) for
      several months to years. As an alternative, salvage treatment of the limited number of
      metastases with either surgery or radiotherapy might postpone the start of ADT even longer.
      The current trial hypothesizes that ADT might be deferred longer following salvage treatment
      as compared to active surveillance.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Androgen deprivation therapy free survival.</measure>
    <time_frame>From date of randomization until androgen deprivation therapy is started, assessed up to 2 years.</time_frame>
    <description>Androgen deprivation therapy free survival will be calculated from randomization until androgen deprivation therapy is started.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire 1.</measure>
    <time_frame>At 3, 6, 9, 12, 15, 18, 21, 24 months</time_frame>
    <description>Questionnaire: European Organisation for Research and Treatment of Cancer Quality Of Life C30 (EORTC QLQ C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life questionnaire 2.</measure>
    <time_frame>At 3, 6, 9, 12, 15, 18, 21, 24 months</time_frame>
    <description>Questionnaire: Short Form (36) Health Survey (SF36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire 3</measure>
    <time_frame>At 3, 6, 9, 12, 15, 18, 21, 24 months</time_frame>
    <description>Questionnaire: EORTC QLQ PR25</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Active clinical surveillance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active monitoring of patients with low volume metastases with Prostate Specific Antigen (PSA) and sequential imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salvage treatment of metastases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgical or radiotherapy treatment of metastases.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surveillance</intervention_name>
    <description>Active clinical surveillance</description>
    <arm_group_label>Active clinical surveillance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Salvage treatment</intervention_name>
    <description>Surgical removal of metastases, or stereotactic body radiotherapy of metastases.</description>
    <arm_group_label>Salvage treatment of metastases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven diagnosis of prostate cancer (PCa)

          -  Biochemical relapse of PCa following radical local prostate treatment

          -  N1 and M1a/b disease on imaging, with a combined maximum of 3 synchronous lesions.

          -  World Health Organization (WHO) performance state 0-1

          -  Exclusion of local relapse

          -  Age &gt;=18 years old

          -  Signed informed consent

        Exclusion Criteria:

          -  Serum testosterone level &lt;50ng/ml

          -  Symptomatic metastases

          -  PSA rise while on active treatment with luteinizing hormone-releasing hormone
             (LHRH)-agonist, LHRH-antagonist, anti-androgen, maximal androgen blockade, oestrogen

          -  Previous treatment with cytotoxic agent for PCa

          -  Treatment during the past month with products known to influence Prostate Specific
             Antigen (PSA) levels (e.g. fluconazole, finasteride, corticosteroids,â€¦)

          -  Disorder precluding understanding of trial information or informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gert De Meerleer, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2012</study_first_submitted>
  <study_first_submitted_qc>March 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

